Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-04-25
1997-02-04
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 13, 530300, 530326, 530382, A61K 3803, A61K 3810
Patent
active
055997902
ABSTRACT:
The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.
REFERENCES:
Altieri, et al., "A Unique Recognition Site Mediates the Interaction of Fibrinogen with the Leukocyte Integrin Mac-1 (CDIIb/CD18)", J. Biol. Chem., 265: 12119-12122 (1990).
Altieri, et al., "Oligospecificity of the Cellular Adhesion Receptor MAC-1 Encompasses an Inducible Recognition Specificity for Fibrinogen", J. Cell Biol., 107: 1893-1900 (1988).
Altieri, et al., "Binding of Fibrinogen to Human Monocytes", J. Clin. Invest., 78: 968-976 (1986).
Altieri, et al., "Occupancy of CDIIb/CD18 (Mac-1) Divalent Ion Binding Site(s) Induces Leukocyte Adhesion", J. Immunol., 147: 1891-1898 (1991).
Erban and Wagner, "A 130-kDa Protein on Endothelial Cells Binds to Amino Acids 15-42 of the B.beta. Chain of Fibrinogen", J. Biol. Chem., 267: 2451-2458 (1992).
Fair, et al., "Immunochemical Mapping of the Conformation of Human Fibrinogen", J. Biol. Chem., 256: 8018-8023 (1981).
Furlan, et al., "Plasmic Degradation of Human Fibrinogen", Biochem. Biophys. Acta, 400: 95-111 (1975).
Hynes, "Integrins: A Family of Cell Surface Receptors", Cell, 48: 549-554 (1987).
Languino, et al., "Fibrinogen-Endothelial Cell Interaction in Vitro: A Pathway Mediated by an Arg-Gly-Asp Recognition Specificity", Blood, 73: 734-742 (1989).
Pizzo, et al., "The Effect of Plasmin on the Subunit Structure of Human Fibrinogen", J. Biol. Chem., 247: 636-645 (1972).
Price, et al., "In Vivo Inhibition of Neutrophil Function in the Rabbit Using Monoclonal Antibody to CD18", J. Immunol., 139: 4174-4177 (1987).
Ruoslanti and Pierschbacher, "New Perspectives in Cell Adhesion: RGD and Integrins", Science, 238: 491-497 (1987).
Springer, "Adhesion Receptors of the Immune System", Nature, 346: 425-434 (1990).
Edgington Biotechnology IC: 383-389 (1992).
Ward Therapeutic Immunology 1: 165-171 (1994).
Languno et al Cell 73: 1423-1434 (1993).
Altieri et al J Biol Chem 268 1847-1853 (1994).
Friendlander et al. Science 270:1500-1502 (1995).
J. Virology 69: 5951-5958 (1995), Goldman et al.
Frishman et al. American Heart J. 130: 877-892 (1995).
Altieri Dario C.
Languino Lucia R.
Thornton George B.
Chan Christina Y.
Fitting Thomas
Gambel Phillip
The Scripps Research Institute
LandOfFree
Fibrinogen .gamma. chain polypeptide and compositions thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibrinogen .gamma. chain polypeptide and compositions thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibrinogen .gamma. chain polypeptide and compositions thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-678623